BSP:Q1UE34 (USA)
Business Description
Quest Diagnostics Inc
NAICS : 621511
SIC : 8071
500 Plaza Drive, Secaucus, NJ, USA, 07094
Description
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.17 | |||||
| Equity-to-Asset | 0.48 | |||||
| Debt-to-Equity | 0.72 | |||||
| Debt-to-EBITDA | 1.86 | |||||
| Interest Coverage | 14.02 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.69 | |||||
| Beneish M-Score | -2.56 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -8 | |||||
| 3-Year EBITDA Growth Rate | 6.9 | |||||
| 3-Year EPS without NRI Growth Rate | 43.2 | |||||
| 3-Year FCF Growth Rate | 6.7 | |||||
| 3-Year Book Growth Rate | 11.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | -4.86 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | -3.75 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 99.91 | |||||
| 9-Day RSI | 96.05 | |||||
| 14-Day RSI | 86.51 | |||||
| 6-1 Month Momentum % | 3.38 | |||||
| 12-1 Month Momentum % | -7.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.54 | |||||
| Quick Ratio | 1.42 | |||||
| Cash Ratio | 0.5 | |||||
| Days Inventory | 10.94 | |||||
| Days Sales Outstanding | 47.12 | |||||
| Days Payable | 19.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.86 | |||||
| Dividend Payout Ratio | 0.17 | |||||
| 3-Year Dividend Growth Rate | 6.9 | |||||
| Forward Dividend Yield % | 1.86 | |||||
| 5-Year Yield-on-Cost % | 2.75 | |||||
| 3-Year Average Share Buyback Ratio | 4.1 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 37.2 | |||||
| Operating Margin % | 19.74 | |||||
| Net Margin % | 14.02 | |||||
| ROE % | 23.46 | |||||
| ROA % | 11.11 | |||||
| ROIC % | 14.42 | |||||
| ROC (Joel Greenblatt) % | 82.84 | |||||
| ROCE % | 17.79 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 11.69 | |||||
| Forward PE Ratio | 15.04 | |||||
| PE Ratio without NRI | 11.69 | |||||
| Shiller PE Ratio | 18 | |||||
| Price-to-Owner-Earnings | 11.64 | |||||
| PS Ratio | 1.61 | |||||
| PB Ratio | 2.57 | |||||
| Price-to-Free-Cash-Flow | 10.99 | |||||
| Price-to-Operating-Cash-Flow | 8.85 | |||||
| EV-to-EBIT | 9.73 | |||||
| EV-to-Forward-EBIT | 11.65 | |||||
| EV-to-EBITDA | 8.09 | |||||
| EV-to-Forward-EBITDA | 9.76 | |||||
| EV-to-Revenue | 1.91 | |||||
| EV-to-Forward-Revenue | 2.09 | |||||
| EV-to-FCF | 13.04 | |||||
| Price-to-Projected-FCF | 0.73 | |||||
| Price-to-Median-PS-Value | 0.99 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.5 | |||||
| Earnings Yield (Greenblatt) % | 10.28 | |||||
| Forward Rate of Return (Yacktman) % | 26.75 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil R$) | 55,536.38 | ||
| EPS (TTM) (R$) | 31.646 | ||
| Beta | 0 | ||
| Volatility % | 33.12 | ||
| 14-Day RSI | 86.51 | ||
| 14-Day ATR (R$) | 0.396361 | ||
| 20-Day SMA (R$) | 359.84 | ||
| 12-1 Month Momentum % | -7.22 | ||
| 52-Week Range (R$) | 310.61 - 490.5 | ||
| Shares Outstanding (Mil) | 233.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Quest Diagnostics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||